News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Uroplasty, Inc. (UPI) Announces Issuance of New Apparatus Patent for the Urgent(R) PC Neuromodulation System Stimulator


11/9/2011 11:06:06 AM

MINNEAPOLIS, Nov., 9, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the issuance of United States Patent No. 8,046,082 covering the stimulator used in the Urgent® PC Neuromodulation System. The Urgent PC Neuromodulation System is an office-based, non-surgical system, used to treat overactive bladder syndrome (OAB) and the associated symptoms of urinary urge incontinence, urinary urgency and urinary frequency. The new patent covers the reusable Urgent® PC stimulator. When connected to a thin needle electrode near the ankle to access the tibial nerve, the stimulator delivers current to the sacral nerve plexus that controls bladder and pelvic floor function.

"This newly-issued patent further strengthens our patent position on the Urgent PC System and reinforces our commitment to this product," said David Kaysen, President and CEO of Uroplasty. "We are very pleased that the United States Patent Office has awarded this apparatus patent on the unique stimulator used in our Urgent PC System. Our broad intellectual property portfolio, applicable to the Urgent PC System and its components, now includes apparatus, method, and system patents."

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in

The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:


Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors),
415.568.9349

Medi Jiwani, Vice President, CFO, Treasurer

Chris Gale (Media), 646.201.5431

952.426.6140




SOURCE Uroplasty, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES